Dexcom (DXCM) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.70
- EPS estimate
- $0.61
- EPS surprise
- +14.75%
- Revenue surprise
- +1.40%
- Revenue
- $1.3B
- Revenue estimate
- $1.3B
- Reported
- Jul 30, 2026
Dexcom reported Q2 2026 results on July 30, 2026. Earnings per share were $0.70, ahead of the $0.61 estimate by 14.75%. Revenue was $1.3 billion, in line with the consensus. Compared with Q2 2025, EPS rose about 46% from $0.48, and revenue rose from $1.2 billion.
The longer record shows fast growth. Annual EPS rose from $0.87 in 2022 to $1.51 in 2023, $1.65 in 2024 and $2.09 in 2025, about 2.4 times over three years. Yearly revenue grew about 62%, from $2.91 billion to $4.7 billion. The first half of 2026 added up to $1.26 per share, about 58% above the first half of 2025. Q2 2026 set the EPS high in the table. Over the last 20 quarters, Dexcom beat EPS estimates 15 times, including each of the last five. The largest beat was Q2 2023, at 50.58%. The largest miss was Q1 2022, at 38.84% below. Since Q3 2022, the only misses were Q4 2024 and Q1 2025.
Dexcom reported its third quarter between October 24 and October 30 in each of the past five years. That points to late October 2026 for the next report. It will show whether this year's growth carries into Q3.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $0.61 | $0.70 | +14.75% | $1.3B | SEC |
| Q1 2026 | Apr 30, 2026 | $0.47 | $0.56 | +20.27% | $1.2B | SEC |
| Q4 2025 | Feb 12, 2026 | $0.65 | $0.68 | +4.65% | $1.3B | SEC |
| Q3 2025 | Oct 30, 2025 | $0.58 | $0.61 | +5.85% | $1.2B | SEC |
| Q2 2025 | Jul 30, 2025 | $0.44 | $0.48 | +8.21% | $1.2B | SEC |
| Q1 2025 | May 1, 2025 | $0.33 | $0.32 | −2.20% | $1.0B | SEC |
| Q4 2024 | Feb 13, 2025 | $0.48 | $0.45 | −6.09% | $1.1B | SEC |
| Q3 2024 | Oct 24, 2024 | $0.43 | $0.45 | +3.57% | $994.2M | SEC |
| Q2 2024 | Jul 25, 2024 | $0.39 | $0.43 | +11.34% | $1.0B | SEC |
| Q1 2024 | Apr 25, 2024 | $0.27 | $0.32 | +18.69% | $921.0M | SEC |
| Q4 2023 | Feb 8, 2024 | $0.43 | $0.50 | +16.09% | $1.0B | SEC |
| Q3 2023 | Oct 26, 2023 | $0.34 | $0.50 | +46.76% | $975.0M | SEC |
| Q2 2023 | Jul 27, 2023 | $0.23 | $0.34 | +50.58% | $871.3M | SEC |
| Q1 2023 | Apr 27, 2023 | $0.15 | $0.17 | +16.36% | $741.5M | SEC |
| Q4 2022 | Feb 9, 2023 | $0.27 | $0.34 | +24.45% | $815.2M | SEC |
| Q3 2022 | Oct 27, 2022 | $0.24 | $0.28 | +14.52% | $769.6M | SEC |
| Q2 2022 | Jul 28, 2022 | $0.18 | $0.17 | −7.31% | $696.2M | SEC |
| Q1 2022 | Apr 28, 2022 | $0.13 | $0.08 | −38.84% | $628.8M | SEC |
| Q4 2021 | Feb 10, 2022 | $0.22 | $0.17 | −21.98% | $698.2M | SEC |
| Q3 2021 | Oct 28, 2021 | $0.16 | $0.22 | +37.09% | $650.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Dexcom (DXCM) last report earnings?
Dexcom last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did DXCM beat earnings estimates?
Yes. Dexcom reported EPS of $0.70 for Q2 2026 against a $0.61 estimate — a 14.75% beat.
How much revenue did DXCM report last quarter?
Dexcom reported $1.3B in revenue for Q2 2026, against a consensus estimate of $1.3B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.